Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Pemetrexed in Combination with Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
2009-011611-21Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2009
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed, cisplatin and cetuximab in head and neck squamous cell carcinoma (HNSCC), sponsored by Eli Lilly and Company. Primary endpoint: Progression-free survival. Started Aug 2009; status: completed.
02
Drugs
pemetrexedcisplatincetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2009-011611-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011611-21.